ATX‑304
Experimental fat-loss compound that switches on the AMPK protein; reduced body fat in animals, not proven in humans.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is ATX-304?
ATX-304 (formerly designated O-304) is an experimental compound being developed against obesity and metabolic disease. It is taken by mouth and acts in two ways: it switches on a protein called AMPK, the cell's energy sensor, and pushes the mitochondria (the part of the cell that produces energy) to use more energy, so that cells burn fuel rather than store it. It has not been approved as a medicine and is sold as a research chemical.
In animals and in early studies it reduced body fat and cholesterol, and in fatty-liver models it reduced fat build-up and scarring in the liver. It is in clinical development in humans, but its effect and safety in people have not yet been proven and no human side-effect profile is known; agents that raise energy use in this way can, in theory, also cause overheating. It must not be used in pregnancy or breastfeeding, because there are no safety data. It is not on the anti-doping list, but the general ban on unapproved substances can lead to a sanction in competitive sport.
Mechanism
Stimulates an energy-sensing enzyme, uncouples mitochondria (by mouth)
Development phase
Phase 2 clinical development for obesity + cardiometabolic disease (Amplifier Therapeutics, Cambrian BioPharma). NOT an approved drug.
Indication (under study)
Studied for obesity, heart and metabolic disease, fatty liver
Alternate designation
O-304 (same compound)
Legal status
Investigational (Phase 2), NOT an approved drug. Available on the research-chemical market with the usual label-claim / purity caveats. WADA: NOT prohibited.
Per Sean's curated notes, ATX-304 is a 'free lunch' style fat-loss compound: a 'Pro-Metformin' style compound with elements of BAM-15. Community (Reddit) reports: weight loss on its own was not necessarily 'faster', but in a calorie deficit energy levels felt noticeably better and more enjoyable; zero stimulant-like side effects (no overheating or sleep disruption), a 'neutral-feeling' compound. Another report described a mild 'skin tingling' and a striking reduction in abdominal fat while using it. Several noted that you do not need much of it to get the desired fat-loss effect. (User reports are not clinical evidence.)
A realistic framing matters: ATX-304 is an INVESTIGATIONAL, Phase 2 compound, NOT an approved drug. The overwhelming majority of documented effects come from animal models and early clinical phases, and there is no established human consumer dosing. It is available on the research-chemical market, but it should be treated with the usual label-claim and purity caveats.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Holm E, Vermeulen I, Parween S, López-Pérez A et al. . AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight. 2025.
Katerelos M, Gleich K, Harley G, Loh K et al. . The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury. Biomed Pharmacother. 2024.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Investigational (Phase 2) compound: no published human side-effect profile and no established safe dose; human consumer safety is fundamentally unknown.
- As a dual mitochondrial uncoupler it theoretically raises energy expenditure and heat production; a known class risk of uncouplers in overdose is hyperthermia (overheating), though no human dose threshold is established for ATX-304.
- Increased glucose uptake and improved insulin sensitivity could theoretically cause low blood sugar (hypoglycemia), especially in a calorie deficit or combined with antidiabetic drugs; no human data exists.
- User (non-clinical) reports mention mild skin tingling; these are anecdotal, not verified adverse effects.
- With research-chemical sourced products, label-claim discrepancy and contaminated batches are a real risk: adverse effects from unknown purity cannot be separated from the active compound itself.
- Long-term human hepatic and renal safety is unconfirmed: although it showed liver- and kidney-protective signals in preclinical models, this does not substitute for human long-term safety data.
Contraindications · 6
- Pregnancy and breastfeeding: absolute contraindication – no reproductive safety data for an investigational compound.
- Human consumer (non-trial) use is generally not advised: Phase 2 investigational status, no approved human protocol or dosing.
- Diabetes / use of antidiabetic drugs (insulin, sulfonylureas): theoretical additive hypoglycemia risk – avoid without medical supervision.
- Pre-existing liver or kidney disease: caution warranted – the human hepatic/renal profile is investigational, and the preclinical protective signal does not equal human clinical clearance.
- Heat stress / hyperthermia risk (training in extreme heat, sauna, febrile illness): caution warranted due to the mitochondrial uncoupling mechanism.
- Competitive athletes: although ATX-304 is currently non-listed, the WADA 'S0 non-approved substance' clause may potentially apply – anti-doping agency consultation advised.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching
Holm E, Vermeulen I, Parween S, López-Pérez A et al.
The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury
Katerelos M, Gleich K, Harley G, Loh K et al.
Telegram
Have a question about ATX‑304?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
